TRACON Pharmaceuticals Announces Clinical Data Presentation at Upcoming Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) — TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced the following presentation at the upcoming Connective Tissue Oncology Society (CTOS) 2016 Annual Meeting in Lisbon, Portugal:

Title: TRC105 (Endoglin Antibody) in Combination with Pazopanib in Patients with Advanced Angiosarcoma
Session Title:  Poster Session 2 – Soft Tissue Sarcomas – Poster 110  
Presenter: K. Kumar Sankhala, M.D., Sarcoma Oncology Research Center, Santa Monica, CA  
Location: Corinthia Hotel Lisbon, Lisbon, Portugal  
Date/Time: Friday, November 11, 2016, 10:40 AM – 7:00 PM, Western Europe Time  

About TRC105 (carotuximab)

TRC105 (carotuximab) is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in multiple Phase 2 clinical trials sponsored by TRACON or the National Cancer Institute for the treatment of solid tumor types in combination with VEGF inhibitors. The ophthalmic formulation of TRC105, DE-122, is currently in a Phase 1/2 trial for patients with wet AMD. TRC205, a second generation antibody to endoglin, is undergoing preclinical testing in models of fibrosis. For more information about the clinical trials, please visit TRACON’s website at


TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. The Company is also developing two programs in-licensed from Janssen Pharmaceutica N.V. – TRC253, a small molecule inhibitor of wild type androgen receptor (AR) and multiple AR mutations that confer drug resistance, which is intended for the treatment of men with prostate cancer, and TRC694, a small molecule inhibitor of NF-kB inducing kinase (NIK), which is intended for the treatment of patients with hematologic malignancies, including myeloma. To learn more about TRACON and its product candidates, visit TRACON’s website at

CONTACT: Company Contact:
Casey Logan
Chief Business Officer
(858) 550‐0780 ext. 236

Investor Contact:
Andrew McDonald
LifeSci Advisors LLC